← SynDRA
NILUTAMIDE
SynDRA canonical compound SYN0004991 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | AR |
|---|
| Mechanism of action | Androgen receptor antagonist |
|---|
| Indication | prostate cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- DRD3
- NR1I2
- ESR1
- MLNR
- OPRD1
- NR3C1
- NPY1R
- NPSR1
- NFKB1
- NFE2L2
- MPHOSPH8
- ACHE
- HTR2B
- MC4R
- MC3R
- MBNL1
- MAOA
- LMNA
- KCNH2
- HTR3A
- OPRK1
- OPRM1
- PDE3A
- PDE4A
- TP53
- THRB
- TDP1
- TBXA2R
- SMN1
- SLCO1B3
- SLCO1B1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC29A1
- SAMHD1
- RAB9A
- PTGS2
- PTGS1
- PGR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP19A
- CP1A2
- CP2C9
- CP2CJ
- ESRRA
- GLI3
- GPR151
- NF2L2
- PRGR
Drug classes
- Androgen Receptor Antagonists
- Androgen Receptor Inhibitor
- Androgen Antagonists
- Antineoplastic Agents
- Hormone Antagonists
ATC classes
- L02B · HORMONE ANTAGONISTS AND RELATED AGENTS
Cross-references
Synonyms
- NILANDRON
- Nilandron
- nilandrone
- anandron
- nilandron
- Nilutamida
- NSC-758683
- RU-23908
- Anadron
- Anandron
- Nilandrone
- Nilutamidum
- Aventis Behring Brand of Nilutamide
- Aventis Brand of Nilutamide
- Hoechst Brand of Nilutamide
- Nilutamida [Spanish]
- Nilutamidum [Latin]
- N 8534
- Anandron (TN)
- RU 23908-10
- Nilutamide (USAN/INN)
- Nilutamide [USAN:BAN:INN]
- Nilutamide [USAN:INN:BAN]
- RU 23908
- Nilandron;RU 23908
- NSC 758683
- CHEMBL1274
- CHEBI:7573
- 51G6I8B902
- NCGC00015754-08
- CAS-63612-50-0
- Nilandron (TN)
- SR-01000076034
- BRN 0841906
- UNII-51G6I8B902
- Nilutamide, solid
- MFCD00864670
Reported adverse events
- Interstitial pneumonitis
- Abdominal pain
- Alcohol intolerance
- Arthritis
- Asthenia
- Back pain
- Cataract
- Chest pain
- Chromatopsia
- Constipation
- Cough
- Depression
Look up NILUTAMIDE in the interactive SynDRA portal →